Epipen has a new rival. A low-cost alternative to Mylan's epinephrine autoinjector has been approved. Adamis Pharmaceuticals Corp.'s Symjepi will be sold at less than the price of generic EpiPens.
Epipen has a new rival. A low-cost alternative to Mylan's epinephrine autoinjector has been approved. Adamis Pharmaceuticals Corp.'s Symjepi will be sold at less than the price of generic EpiPens.
Please to comment